Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nfocus CE marks brain aneurysm treatment

This article was originally published in Clinica

Executive Summary

Nfocus Neuromedical has CE marked its flagship product, the Luna aneurysm embolisation system, for sale in Europe. It is designed to treat brain aneurysms both before and after rupture, which can lead to stroke, brain damage and death. Luna blocks blood flow to the aneurysm while providing a scaffold that encourages tissue growth across its opening, creating a plug. It is a self-expandable Nitinol implant that can be delivered via a conventional catheter and opened up to its full size once deployed within the aneurysm. Alternatives include surgery, which is "traumatic and expensive", and coils, which may fail to fully treat the aneurysm, according to Nfocus. The Palo Alto, California firm estimates that up to one in 15 people will develop a brain aneurysm in their lifetime.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT096738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel